Skip to main content
Clinical Trials/NCT00904410
NCT00904410CompletedPhase 4

Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET

Centre Oscar Lambret1 site in 1 country63 target enrollmentStarted: May 1, 2005Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
63
Locations
1
Primary Endpoint
Variation rate of SUV(BSA max)before and after the 1st cycle of neoadjuvant chemotherapy

Study Overview

Brief Summary

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.

We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients.

Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy.

The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.

Detailed Description

Further study details as provided by Centre Oscar Lambret

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age > 18
  • Breast cancer treated by neo-adjuvant chemotherapy (T>2cm)
  • Measurable lesions ,assessed clinically and by ultrasound
  • Delay minimum between biopsy and PET: 15 days
  • PS-WHO: 0

Exclusion Criteria

  • Inflammatory breast cancer (T4d)
  • Diabetic patients unbalanced (glycemia>1.40)
  • Pregnant or lactating women

Arms & Interventions

1

Experimental

Intervention: FDG-PET (Other)

Outcomes

Primary Outcomes

Variation rate of SUV(BSA max)before and after the 1st cycle of neoadjuvant chemotherapy

Time Frame: before and 3 weeks after 1st cycle

Secondary Outcomes

  • Comparison to clinical and ultrasound assessment after the 3rd cycle of chemotherapy(3 weeks after the 3rd cycle)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials